• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Device Consortium Pushes for Stronger Patient Voice in Trials

Device Consortium Pushes for Stronger Patient Voice in Trials

April 12, 2021

Despite all the hoopla about patient engagement, the fact is that the industry is still not really engaged. Recent surveys show more than 80 percent of industry respondents never seek patient input as part of protocol development and almost one-third estimated they sought such input less than 25 percent of the time.

In a 45-page report released last week, the Medical Device Innovation Consortium (MDIC), a partnership of the FDA, NIH and several pharma heavyweights, presented a roadmap of tactics trials can use to increase patient involvement.

MDIC suggested that when researchers engage patients about participating in a trial that they include a discussion about the applicability of exclusion criteria, on the grounds that some criteria may be unnecessarily preventing patients who are otherwise willing to participate.

Patients and advocacy groups should be adequately compensated for their participation in a trial, and a transparent communication plan between them and researchers is essential, MDIC said. It added that clinical trial participants or advisers could continue to play a positive role in supporting interpretation of a study’s findings, and reminded researchers that the process of patient engagement doesn’t end once the patient’s insights have been recorded and evaluated — it may be necessary, for example, for researchers to reconcile patient input with input from other stakeholders, especially if the feedback from both groups are not aligned or are in conflict with each other.

MDIC has 64 members, including Johnson & Johnson, Medtronic, Siemens, Philips, Danaher and Becton Dickinson.

Read the MDIC report here: https://bit.ly/3mtLoIX.

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing